Drugs / MK-4280
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03486873 | Aug 2018 → Aug 2043 expected | cancer, hematopoietic and lymphoid cell neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03486873 ↗ |
| Route | Intravenous | “MK-4280 800mg as IV infusion” NCT03486873 ↗ |